TCM
NEUP

Tang Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

Tang Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-58,333
Closed -$1.89M – 134
2023
Q3 		$1.89M Buy
+58,333
New +$1.26M 0.27% 72

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Tang Capital Management's NEUP Position: Q4 2023 in Review

Tang Capital Management sold out of Neuphoria Therapeutics (NEUP) in Q4 2023, closing a stake of 58,333 shares — an estimated $1.89M sold.

Tang Capital Management first reported a position in NEUP in Q3 2023 and held it in 1 quarter. The position peaked at $1.89M in Q3 2023. 9 funds tracked by Wall St. Rank hold NEUP as of Q4 2023.

  • Tang Capital Management reported no remaining Neuphoria Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Tang Capital Management sold 58,333 Neuphoria Therapeutics shares in Q4 2023, an estimated $1.89M.
  • Tang Capital Management first reported a position in Neuphoria Therapeutics in Q3 2023 and held it in 1 quarter.
  • Tang Capital Management's Neuphoria Therapeutics position peaked at $1.89M in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2023.

Based on Tang Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.